Lantern Pharma Inc. (NASDAQ: LTRN), a clinical-stage, AI-native biopharma company using artificial intelligence and genomic data to develop precision oncology therapies, today announced that it will host a live webinar on Wednesday, September 23, to present the business model, development roadmap, and value proposition of Open-Medicine AI (OMAI), the company’s wholly owned subsidiary building a multi-agentic AI platform for end-to-end therapeutic development.
Panna Sharma, Founder and CEO of Open-Medicine AI, will lead the session, which is intended for investors, biopharma and academic collaborators, and prospective partners. The webinar will explain how OMAI is extending the AI co-scientist approach first commercialized in withZeta.ai — launched in April 2026 and focused on rare and aggressive cancers — into additional disease categories, new therapeutic modalities, and the downstream development challenges that consume most of the time and cost between a validated target and a treated patient. A question-and-answer period will follow the presentation.
Most AI for drug discovery is built at a distance from drug development. Open-Medicine AI was built inside it. Its co-scientists were developed within Lantern’s own clinical programs — with the same data, constraints, regulatory requirements, and decision points that determine whether a molecule reaches patients — and were first put to work in withZeta.ai, which launched in April 2026 and is in use across rare and aggressive cancers.
LTRN shares dipped eight cents, or 4.2%, to $1.85.
